Expert insights on BFPCs for Real-Time Air Monitoring

Recent regulatory changes and technological advances are leading pharmaceutical manufacturers to consider new technologies for microbial air monitoring. EU GMP Annex 1 requires continuous viable air monitoring in Grade A environments for the full duration of critical processing, and its recent revision has changed regulatory attitudes toward real-time detection. Manufacturing is evolving, too: novel biologicals are increasingly being produced with minimal operator intervention in gloved or even gloveless isolators.

These developments have catalyzed broader interest in advanced biofluorescent particle counters (BFPCs) for fluorescence-based continuous active air monitoring in real-time, available in combination with integrated traditional microbial air sampling onto plates. In this webinar, our panel of environmental monitoring specialists will discuss in which settings a BFPC can streamline workflows to boost manufacturing productivity while meeting present and future regulatory demands, and the challenges that need to be overcome.

During the webinar, you will:

• Discover real-time air monitoring in Grade A environments under the latest EU Annex 1.
• Learn how BFPCs pair with traditional sampling to enable real-time decisions.
• Understand regulatory, validation, and operational challenges.
• Explore practical options for integration, qualification, and cost/benefit considerations.

To register go to: BFPCs.

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Laser Cleaning for Biofilm Removal in Pharmaceutical Processing Lines

 Image (C) Tim Sandle

This is the first of three articles extending the discussion of solvent-free decontamination begun in "Laser Cleaning in Pharmaceutical Manufacturing" (July 2026). Where that piece surveyed the method in general terms, this one narrows to the contaminant that most reliably defeats conventional cleaning: established biofilm.

Sanitisation and cleaning are not the same claim

Much of the confusion around biofilm control in pharmaceutical processing comes from conflating two distinct regulatory obligations. Sanitisation asks whether viable organisms have been inactivated. Cleaning asks whether residue has been removed to a defined limit. A biocide can satisfy the first while leaving the second entirely unaddressed.

This matters because biofilm is not primarily a population of cells. It is a structure — a hydrated matrix of extracellular polymeric substances (EPS), largely polysaccharide, protein and extracellular DNA, within which cells are embedded. When a sporicidal or oxidising agent passes over that structure, the cells within it may well be killed. The matrix, and the killed biomass inside it, remains adhered to the surface.

From a cleaning validation standpoint, that material is residue. It is organic carbon on a product-contact surface. It will register on total organic carbon (TOC) rinse analysis. It remains a nutrient reservoir and an adhesion scaffold, so the surface is preferentially recolonised — which is the usual explanation when a water system returns to alert levels within days of a successful sanitisation cycle.

Why the matrix resists chemistry

Three mechanisms are well described in the literature and worth restating in a cleaning context.

First, diffusion limitation. The EPS matrix retards the penetration of biocide to the deeper cell layers, so the effective concentration reaching the substrate interface is lower than the concentration applied. Contact time specified from planktonic suspension testing therefore systematically understates what an adherent biofilm requires.

Second, reaction and neutralisation. Oxidising agents are consumed by the outer matrix itself. The material closest to the stainless steel — the layer that actually determines whether the surface is clean — is the last to be reached and the least aggressively treated.

Third, phenotypic tolerance. Cells in the sessile state express a physiology markedly different from their planktonic counterparts, including reduced metabolic rate in the deeper strata, and are correspondingly less susceptible to agents whose action depends on active metabolism.

The practical consequence is familiar to anyone who has investigated a recurring bioburden excursion: the cycle passes, the rinse sample passes, and the organism returns. The organism returns because its house was never demolished.

What laser ablation does differently

Pulsed laser cleaning is not a disinfection process. It is a removal process, and that is precisely the point of interest here.

The mechanism was outlined in the earlier article: a pulsed source, typically operating around 1064 nm, delivers energy in discrete packets to the surface. Removal depends on the differential absorption between the layer to be removed and the substrate beneath it. Electropolished 316L stainless steel is strongly reflective at that wavelength; hydrated organic material is not. Energy is therefore preferentially deposited in the contaminant.

For biofilm specifically, the water content of the matrix is an advantage rather than an obstacle. Rapid, localised energy deposition produces vaporisation and mechanical spallation within the EPS layer, so the matrix is lifted from the surface as particulate and vapour and drawn away by local extraction. Cells and matrix are removed together, as a single layer. There is no distinction between killed and living material, because neither is left behind.

Two secondary properties follow from this, both relevant to a contamination control strategy:

The process is dry. No cleaning agent is introduced, so no cleaning agent requires its own removal validation — the point made under ICH Q7 Section 12.7 in the earlier article applies with equal force here. Equally, no rinse step is required, which removes one water-contact operation, and therefore one recolonisation opportunity, from the sequence.

The process is monitorable. Because ablation produces a characteristic acoustic and optical emission that changes as the contaminant layer is cleared and the substrate is reached, end-point detection is at least in principle available in real time, rather than only through offline swab and rinse sampling.

Where it fits, and where it does not

It would be misleading to present laser ablation as a general replacement for clean-in-place. It is a line-of-sight method. It cannot address the interior of installed pipework, a dead leg, or the inner geometry of a closed system, and no configuration of optics changes that constraint.

The realistic applications are surfaces that can be presented to the beam: dismantled filling line components, gaskets and seal faces, vessel interiors with adequate access, transfer and change parts, and equipment removed from service for investigation or refurbishment. In water systems, the honest positioning is not as a CIP substitute but as a remediation step for components taken out of the loop, and for the accessible surfaces of tanks and distribution points where an established biofilm has proved refractory to repeated sanitisation.

Two further limitations deserve to be stated plainly. Particulate is generated and must be captured; extraction and filtration are part of the equipment, not an optional accessory. And surface finish must be verified rather than assumed: parameters selected below the ablation threshold of the substrate should leave roughness unchanged, but this is a matter for demonstration during process development, with Ra measurement before and after, not a property to be taken on trust.

Verifying removal rather than inactivation

Because the claim is removal, verification should be built around removal endpoints.

A defensible package would combine direct surface sampling — swabs and contact plates for viable recovery — with TOC on a defined rinse or extraction, since TOC responds to matrix material that viable counts will miss entirely. Where the question is specifically whether the structure has gone, microscopy of coupons carrying a grown biofilm is the most direct evidence available, and scanning electron microscopy or confocal imaging of treated versus untreated coupons is far more persuasive to an inspector than a plate count.

Coupon studies using a defined organism grown to an established biofilm under controlled conditions, then treated and examined, provide the underlying evidence. Recovery studies for the analytical method, and a demonstration that results are reproducible across operators and across the geometry of the actual part, complete the picture in the usual way.

The regulatory framing

None of this sits outside existing expectations. EU GMP Annex 1 (2022) requires a documented contamination control strategy and asks manufacturers to justify the methods within it; a non-chemical, non-contact removal step is straightforward to describe in those terms, particularly where it reduces interventions. Section 6 of the same annex, covering utilities, is explicit about the need to control biofilm in water systems, and a method aimed at the matrix rather than at viability addresses that requirement directly.

ICH Q7 Section 5.2 requires equipment cleaning procedures to be adequate and documented, and Section 12.7 sets the expectations for cleaning validation. A process that introduces no cleaning agent simplifies the residue calculation under the health-based exposure limit framework, because the only residue at issue is the one being removed.

Part 2 will take this comparison into the cleanroom itself, setting laser cleaning against solvent-based and CIP methods in an ISO Class 5 context, with particular attention to particle generation and the documentation burden each approach carries.

Alex Chen writes on industrial surface decontamination and works with laser cleaning system manufacturers supplying regulated industries. Further technical material on laser cleaning for manufacturing is available at LaserCleanerPro.

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Pharmaceutical Water Systems Under Greater Microbiological Scrutiny: Emerging Monitoring and Risk-Management Strategies

Pharmaceutical water systems can produce acceptable microbiological results while still developing conditions that warrant closer investigation. A culture result describes what was recovered from one sample under particular test conditions. It does not necessarily reveal what is occurring elsewhere in a storage vessel, distribution loop, membrane surface, valve, branch connection, or point-of-use assembly. 

That distinction matters because the microbiological condition of a water system can change with temperature, circulation, production demand, sanitisation, maintenance and periods of reduced use. WHO guidance consequently places emphasis on representative sampling, ongoing monitoring, trend analysis and periodic review of water-system performance rather than relying on isolated test results. 

Greater scrutiny, therefore, should not be interpreted simply as collecting more samples. More useful assurance comes from understanding whether microbiological findings remain consistent with the way the system is operating and whether small changes are being recognised before they develop into recurring excursions. 

A compliant sample does not describe the whole system 

Microbiological risk can change between the point at which water is generated and the point at which it is used. Storage vessels, distribution loops and individual points of use introduce different physical conditions, and the same water may behave differently in sections with different flow, turnover or usage patterns. 

FDA guidance on high-purity water systems notes that microorganisms can occur both as free-floating cells and as biofilms attached to surfaces, with attached populations capable of continually releasing organisms into the water. Contamination may therefore be unevenly distributed within a system. 

That makes location an important part of interpretation. 

• An acceptable result at generation: It provides evidence about the treatment stage, but not necessarily about downstream distribution. 

• A change at one point of use: It may direct attention toward local piping, fittings, hoses, flow conditions, sampling technique, or nearby surfaces.

• Similar changes across several locations: They are more difficult to explain as a single point-specific event and may warrant review of a wider part of the loop.

• An unusual organism: Identification can provide context that a colony count alone cannot, particularly when a similar organism appears repeatedly.

Pharmaceutical Microbiology Resources has previously highlighted how seasonality, temperature, velocity, system design, and maintenance can influence microbial contamination in pharmaceutical water systems. 

The implication is important: microbiological results should be read against the physical system that produced them. 

Trend analysis should look for movement, not just excursions 

A water system does not need to exceed an action limit before its behaviour becomes interesting. 

Imagine a sampling point that has historically produced low, stable recoveries. Across several monitoring cycles, counts begin to rise, although every result remains within the established range. Nothing has formally failed, yet the baseline has changed. 

That is where trend analysis becomes useful. 

WHO guidance recommends routine trend analysis and the use of historical data when establishing and reassessing alert and action levels. The most useful trend review can bring several variables together: 

• Count: Is the microbial level moving away from its established baseline?

• Frequency: Are higher recoveries occurring more often?

• Location: Is the change isolated or appearing across connected points?

• Identity: Are similar organisms recurring?

• Timing: Did the pattern begin after maintenance, sanitisation, shutdown, or a use change?

• Operating data: Did flow, temperature, conductivity, TOC, or another relevant parameter change at a similar time?

Such analysis is more informative than simply plotting CFU values against dates. A gradual shift that remains within specification may be a very different signal from a single isolated excursion followed by an immediate return to baseline. 

Alert levels also need to remain system-specific. Historical performance, qualification data, and investigation results provide a stronger basis for setting and reviewing those levels than simply adopting a generic number from another facility. 

The sampling plan should reflect how the water is actually used 

Representative sampling is not achieved merely by placing sample points at convenient locations.  Generation, storage, distribution and point-of-use locations provide different types of evidence. A treatment-stage sample may demonstrate that the purification process is producing water of the intended quality, while a point-of-use sample can reveal what happens after that water has travelled through the distribution network. 

WHO guidance calls for sampling at points of use or suitable dedicated sample points and for consistent sampling methods. 

An effective programme should therefore be able to answer three practical questions: 

1. Coverage: Are the locations capable of detecting changes in the different parts of the system? 

2. Frequency: Does the schedule reflect the history, intended use and risk profile of each part of the system?

3. Consistency: Are flushing, collection, handling, and testing procedures sufficiently controlled to make results comparable over time?

Frequency deserves particular attention. More frequent sampling is not automatically more informative if the locations are poorly chosen or the results cannot be interpreted consistently. Conversely, a long-established system may need additional sampling following an intervention, abnormal trend, prolonged shutdown, or significant modification. 

FDA guidance has also emphasised the value of point-of-use sampling because microbial contamination can occur within the distribution system after water has passed through the primary treatment stages. 

In other words, the sampling network should tell the story of the system rather than merely satisfy a schedule. 

Downtime can create a different microbiological state 

Extended downtime deserves more attention than it often receives because system conditions during inactivity are not necessarily representative of normal production. 

Recent research into pharmaceutical water-treatment equipment has reported that downtime can create conditions associated with membrane biofouling, including abrupt flow reductions, changes in dissolved oxygen, and nutrient accumulation. Such changes may encourage microbial colonisation and influence later membrane performance. 

A return-to-service event should therefore be viewed as a transition that may require its own assessment. 

• Before restart: What remained filled or stagnant during the interruption? 

• During restart: What flushing, recirculation or sanitisation sequence was used?

• Immediately afterward: Do early samples resemble the established microbiological baseline?

• During subsequent operation: Does the system remain stable, or does an unusual pattern emerge after several cycles?

The last question is easily overlooked. One acceptable sample after restart does not necessarily establish that the system has fully returned to its previous condition. Later results may provide a more useful indication of whether control has actually been restored. 

Broader water-treatment investment is also moving toward more sophisticated monitoring and treatment infrastructure. India's membrane water and wastewater treatment market, for example, was valued at about USD 520 million in 2025 and is projected to reach USD 891.2 million by 2032, with an estimated 8% CAGR. 

That broader development does not translate directly into pharmaceutical water requirements, but it illustrates the scale of investment in treatment infrastructure and the growing importance of systems that can maintain consistent process performance under changing operating conditions. 

Repeated recovery changes the investigation 

Recurring microbial recovery from one location should not automatically be labelled as biofilm. It should, however, change the questions being asked. FDA guidance describes biofilm-associated organisms as a possible continuing source of contamination because attached populations can release microorganisms back into the water. 

Where the same location repeatedly generates unusual findings, investigators can examine: 

• Hydrodynamics: Is circulation adequate, or could the location experience low flow or poor turnover? 

• Hardware: Could valves, branches, fittings, gaskets, or other components create difficult-to-sanitise surfaces?

• Sanitisation: Does the selected intervention reach the relevant area under actual operating conditions?

• Maintenance: Has the location been opened, modified, or repaired?

• Sampling: Could the sampling process itself be introducing variability?

The maintenance history can be especially valuable. Pharmaceutical Microbiology Resources has previously discussed intervention-related contamination risks, including work involving valves and pipework. 

For microbiology teams, that means engineering records should not be treated as separate documentation that becomes relevant only during a formal deviation. When an unusual organism repeatedly appears at one location, maintenance and change-control history may provide the missing explanation. 

Online monitoring is valuable when it adds context 

The wider water-quality market is already moving toward more continuous monitoring. Online water-quality monitoring systems accounted for 25% of the broader water-quality testing and monitoring market in 2025, reflecting growing demand for continuous visibility rather than reliance solely on periodic measurements. 

Pharmaceutical manufacturing has good reason to examine that direction carefully, but not to confuse greater data frequency with microbiological assurance. 

WHO guidance supports the use of online monitoring for parameters such as temperature, flow, pressure, conductivity and TOC alongside offline physical, chemical and microbiological testing. The real benefit appears when those datasets are interpreted together. A change in flow may provide context for a later rise in microbial recovery. A temperature deviation may help explain why one period produced different results from another. A conductivity change may indicate an upstream process problem that would otherwise appear disconnected from downstream observations. 

No single parameter proves the cause of a microbiological event. Combined evidence can, however, narrow the investigation considerably. Rapid microbiological methods can shorten the delay between sampling and detection. Pharmaceutical Microbiology Resources has previously described rapid detection approaches for pharmaceutical-grade water as an alternative to conventional methods with longer time-to-result. 

Their value depends on method suitability, validation, and appropriate interpretation. A faster result is useful only when it represents meaningful information about the microbiological question being investigated. 

An excursion should connect the laboratory result to the system history 

Repeat testing may be necessary after an unexpected result, but a repeat sample should not become the entire investigation. 

WHO inspection guidance points toward a wider review that can include the water-system diagram, sampling programme, alert and action levels, trend data, periodic system review, changes, deviations, maintenance and repair records, and calibration of critical instruments. 

A practical investigation can therefore proceed in stages: 

• Verify: Confirm that sampling, transport, laboratory controls and test execution were satisfactory. 

• Localise: Determine whether the finding is limited to one point, branch or equipment component. 

• Compare: Review historical counts, organism identity and trends from the affected location.

• Reconstruct: Examine maintenance, sanitisation, shutdowns, modifications and deviations around the event.

• Correlate: Compare microbiological findings with relevant operating parameters.

• Confirm control: Assess whether corrective action produces sustained improvement rather than one acceptable follow-up result.

That final distinction matters. A temporary reduction in microbial counts does not necessarily demonstrate that the underlying cause has been removed. Sustained performance provides stronger evidence that control has actually been restored. 

Building a stronger picture of microbiological control 

Pharmaceutical water assurance is becoming less dependent on any single measurement and more dependent on how different pieces of evidence fit together. 

Microbial counts and organism identity remain central. Sampling location determines what those results can represent. Trend analysis shows whether behaviour is stable or changing. Engineering and operational records provide context. Online parameters can help identify when the physical state of the system has shifted, while rapid microbiological methods can reduce the time between detection and response.  The strongest monitoring programmes connect all of those elements. 

A compliant sample remains important, but compliance at one moment does not by itself demonstrate sustained control. Greater microbiological scrutiny is ultimately about recognising meaningful changes earlier, understanding why they may have occurred, and determining whether corrective measures have restored the system rather than merely produced another acceptable test result. 

For pharmaceutical manufacturers, that is the difference between testing the water and demonstrating control of the water system that produces and distributes it. 

About the Author 

Shammi Thakur is Research Director at Vyansa Intelligence, with more than 15 years of experience in strategic market intelligence, industry research, forecasting, and competitive analysis across healthcare, pharmaceuticals and biotechnology. His work focuses on translating complex industry developments into practical insights for business and industry professionals. 

 

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Disinfectant validation - Part 1 | RSSL Pharma Focus Webinar

 

 Join Dr Tim Sandle and RSSL's Nikki Boyle as they guide you through designing laboratory tests to assess disinfectant efficacy, ensuring both regulatory compliance and real-world relevance.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Don’t Know Where to Start? How to Set Off on Your Journey to Microbial QC Automation

 

You’ve probably heard of the growing trend toward automating microbial quality control (QC), and the benefits of faster and more reliable results, easier compliance, and fewer error-prone manual tasks sounds attractive to you—but you don’t know where and how to start? Then you’re not alone: in my experience this apprehension is very common, and it’s quite understandable why. The stream of new information can be overwhelming and you need the resources to get a project done. Automated systems for routine procedures in QC are grabbing your attention, but where do regulatory compliance, financial considerations, and the impact on your staff in their daily work come into the equation?

By Anne Weeks, Automation & Robotics Specialist, Merck

My suggestion is to move forward step by step once you have assembled your team of committed stakeholders. Certain questions are sure to come up sooner or later, and I’m using them to give this article its structure:

► Who should be in the project team?

► Is external support advisable?

► Is your facility ready for QC automation?

► How will your QC personnel be affected?

► What do validation, qualification and implementation involve?

► How do you weigh the benefits against the costs?

► How pitch a convincing business case to management?

Who should be in the project team?

It is usually a particularly committed person that sets the wheel in motion. This change agent can be a validation team member, the operations director, a QC manager or whoever takes the initiative. The present function in the company doesn’t really matter much because the first step will be to set up a team that brings together the expertise needed to assess the feasibility of automation. Commitment and a shared vision to succeed seem to matter more. . The change agent will usually have gained some knowledge of automation by gathering information at conferences, speaking to colleagues, suppliers, possibly peers from other facilities or by other means.

In my experience, the facility’s willingness to embark on the path to automation is stronger when there is a problem for which a good long-term solution has not yet been found. Limited availability of skilled staff or the need to expand QC testing volumes can also be the initial drivers. Acting this way makes sense—it adds the additional benefit of putting the issue to rest. Having said that, most facilities will be looking into QC automation for one reason or another in the coming years, and starting early avoids the need to deal with it under pressure at a later date.

Among the members of the project team there should be an internal IT specialist because automation regularly goes hand-in-hand with digitalization, which multiplies the benefits of automation. Any changes in QC testing will have to be reflected in the management and evaluation of data, and the new solution must be integrated into the existing IT ecosystem. Getting that done in compliance with regulations will be one of the most important tasks, which is why an internal compliance and regulation specialist should also participate. A services specialist should also be part of the team to clarify if the capabilities and resources to service the automated equipment are available internally or if it is better to look for full coverage by the supplier. Larger companies may have a validation team or a technology & innovation group that will support or even drive the process toward automation. In a balanced project team, everyone will have a role to play.

Is external support advisable?

To ensure that the project team addresses, discusses and acts upon all the relevant issues, it makes sense to get support from outside the company right from the onset. Automation and robotics solutions are still quite new so it is probably difficult to find someone with the needed first-hand expertise and experience who is not affiliated to a supplier. Among the suppliers, those with a wide spectrum of automation and robotics solutions will usually be better placed to assess the requirements for the tasks a pharmaceuticals manufacturer may, over time, want to automate.

The tests that can, in principle, be automated include:

► Environmental monitoring

► Bioburden testing

► Sterility testing

► Sample processing, incubation, and final count

At Merck, we have specialists in these fields who have collaborated with pharmaceutical companies in actually developing such systems and who are well acquainted with both compendial and rapid QC automation methods and their validation. Their contacts can also help to get the right people together. In one recent case, I could make a facility aware that at another of the company’s sites in a different country they were having similar plans. Moving forward in tandem can save resources by avoiding to go through evaluation of automation separately. This also makes planning and validation more efficient. Suppliers who have supported their customers for many years in microbial QC are likely to have a better understanding of how regulatory compliance is achieved than integrator companies that specialize more on the robotics than the test applications.

Is your facility ready for QC automation?

Most facilities should be either ready for automation or convertible. There might have to be a new space created that is automation or robotic “friendly” or a modified space as automation usually takes up somewhat more room than the corresponding manual methods. Requirements differ considerably depending on the application. While some automated systems are fixed to one place over their entire lifetime, others such as EM robots move between sampling locations, either regularly or at intervals.

Moving robots, like the ones we are developing for environmental monitoring, require:

► Level flooring with no slopes or steps

► Corridors dimensioned to allow robot movement

► Sufficiently sized elevators If the facility covers multiple levels

► Doors that open and close automatically

► Large enough locks with no physical obstacles to overcome

Other automated solutions for environmental monitoring are stationary and perform a different set of tasks, for example the Growth Direct^® System we offer for fully automated processing and incubation of microbial quality control samples, coupled with rapid colony detection. Stationary systems like our solution for fully automated, high-throughput bioburden testing are sizeable and quite heavy so the floor has to be strong enough to support them. A general requirement for automated systems is that data connectivity must be available throughout for the transfer of digital data.

Constructing a new manufacturing facility makes the adoption of automation easier because operation does not need to be halted during conversion. Future requirements in an industry with constantly rising regulatory demands can be also taken into account from the onset, leaving more options.

How will your QC personnel be affected?

To many employees, automation carries the risk of redundancies—understandably so because this has been the consequence in some other sectors, for example the car industry. However, in microbial QC, reducing staff levels is rarely the primary goal, or even realistic. Given the constantly increasing QC testing volumes, particularly for biologics and advanced therapies, the real objective is to use the existing expertise more effectively. QC departments are already struggling to attract, maintain and train the personnel they need.

Automation can free up staff hours for higher-value activities like:

► Data interpretation

► Method development

► Root-cause investigations

It helps to create a more engaged workforce. Many facilities are already contending with a limited availability of skilled personnel while a substantial share of staff time is being spent on repetitive manual tasks such as plate preparation, sample transfers, incubation management and documentation. This is why a key early role of the project team, apart from setting the path to automation, should be to dispel concerns among the QC personnel about job losses. Routinely operating the automated systems shouldn’t become much of an issue either. Reputable suppliers mostly offer hands-on training courses for personnel along with the automation systems they offer.

 

Some tests don’t lend themselves well to physical automation due to the very different protocols and consumables used, for example sterility testing. However, configurable software guidance at the point of handling to support operators to follow SOPs can carry many of the same benefits of automation. Our M-Trace^® solution for sterility testing, for example, builds on step-by-step verbal or screen-displayed instructions and, when each step is completed, feedback from the operator, combined with simultaneous real-time data capture. This significantly lowers the risk of handling errors while ensuring data integrity and traceability.

A few things will continue to be done conventionally. It’s important that manufacturers maintain the capability among their staff to perform manual testing for when maintenance is performed on the automated system as well as for validation and revalidation purposes, given that they constantly have to deal with new matrices. So it’s not either manual or automated testing—they complement each other.

What do validation, qualification and implementation involve?

A common misconception about QC automation is that regulators won’t like it because it’s unconventional. In fact, the opposite is true. Regulation is gradually evolving to make automation not just possible—it has started to promote such technologies. Automated systems operate with consistent precision and repeatability, which reduces the risks of cross-contamination and human errors. This leads to more robust test results and fewer false positives, improving both reliability and efficiency. The comprehensive data that is automatically captured can be analyzed to detect trends and deviations early, accelerating investigations into out-of-specification results.

Automation and robotics, in combination with digitalization, also

► Improve data integrity and audit readiness

► Reduce the risk of investigations becoming necessary

► Provide the ability to better fulfill future regulatory requirements such as electronic records or advanced analytics

In a nutshell, automation comes with digitalization as both an enabler and an amplifier of efficiency and reliability gains. Expect regulators to know about the potential to improve compliance. If in doubt about anything, it should be possible to discuss this with them.

Suppliers should be able to provide documentation and services to support validation, qualification and implementation of their automated systems. This eases the burden for the pharmaceutical manufacturer significantly. The Growth Direct^® System, for example, has been validated in as little as three months. The time this takes depends primarily on how the system is used and on the resources the company is able to make available.

How do you weigh the benefits against the costs?

In practice, discussions about return on investment (ROI) and payback periods often start with an all-too-narrow focus on direct labor cost savings. Maybe it is intuitive to assume that the overriding purpose of automating repetitive tasks like plate handling, air sampling, or incubation is to reduce the need for manual activities and documentation. But in reality, there is far more to it.

A more meaningful approach is to view ROI in terms of the total cost of quality. While many benefits are difficult to quantify, ignoring them leaves you with a wholly incomplete calculation. From a business perspective, it’s more meaningful to distinguish between two types of benefits. At operational level they include direct savings and capacity gains, for example due to reduced overtime, the ability to handle higher sample volumes without proportional increases in headcount, and the elimination of manual testing steps. Because these can be translated into tangible metrics, they form the quantitative foundation of most business cases.

The second type consists of strategic benefits, including:

► Greater throughput flexibility

► Better data integrity and audit readiness

► Easier design and execution of contamination control strategies

► Reduced risk of costly issues like deviations, rework, valuable product going to waste, and interventions by regulatory bodies

► Easier compliance when regulatory requirements increase or change

► Improved attractiveness of the QC lab for existing and new personnel

Automation can deliver value across all of these areas, at various levels, not just through labor efficiency. Robotic and automation systems operate tirelessly and with precision, and their standardized motions are exactly the same, day in, day out. Facilities that offer the flexibility to operate seven days a week and for long hours, or even 24/7, have the competitive edge in a faster moving market where demand fluctuates.

How pitch a convincing business case to management?

While the benefits of automation are widely recognized, the real challenge often lies in securing investment. Automation of microbial QC competes with other projects for both funding and attention, which is why the project team needs to clearly articulate its value to management. This means presenting a structured case that links the total cost of ownership to tangible value drivers and aligns with the financial and operational criteria used by the manufacturing and finance stakeholders.

While strategic benefits are harder to quantify, they are highly relevant at corporate level, where longer-term considerations, brand reputation, and improbable but potentially severely damaging events are weighed alongside short-term financial returns. Taking all types of advantages into account allows investments in microbial QC automation to be assessed on an equal footing with more traditional manufacturing investment cases.

Conclusion

Robotics and automation, paired with digitalization, carry a huge potential for microbial QC in the pharmaceutical industry. Throughput becomes more flexible, manual handling errors are avoided, and results become repeatable and thus more reliable. The real-time captured data provide actionable insights: trends can be monitored, deviations flagged earlier, and investigations into out-of-specification results accelerated. Scheduling is streamlined, documentation burdens reduced, and overall operational efficiency enhanced. Automated data recording and storage across the entire workflow—from material selection to final reporting—ensures full data integrity and traceability.

The first step on the path to automation is usually to set up a team that looks into the feasibility of the transition. This team should include IT and regulation specialists, as well as an external expert with first-hand knowledge of and experience with automation solutions. Their role is to weigh the investment against the calculable as well as the strategic benefits. If deemed beneficial, they will be in a good position to make the case to management.

CTA: Get in touch with a specialist of ours for QC robotics, automation and digitalization: Request consultation

---

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)